poisar

Stock

Crescent Biopharma, Inc. CBIO

$16.31-4.79%

Overview

CBIO market data

Price History

CBIO price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$14.97
Diluted earnings per share over the trailing twelve months.
Beta
1.23
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$8.72 – $27.41
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $585.1 · P/B 0.81 · P/S 49.24.

Company news

9 captured
8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)SEC EDGAR · Jul 15, 2026, 8:58 PM
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobenewswire Inc · Jul 15, 2026, 11:15 AM
Reported Earlier, Crescent Biopharma Prices Public Offering Of 8,094,793 Ordinary Shares At $14.50 Per Share, Expects $125.0M In Gross ProceedsBenzinga · Jul 15, 2026, 7:08 AM
Crescent Biopharma shares are trading lower after the company announced a proposed public offering.Benzinga · Jul 14, 2026, 8:04 PM
Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms UndisclosedBenzinga · Jul 14, 2026, 8:02 PM
Crescent Biopharma Files Prospectus For Offering $500M Mixed ShelfBenzinga · Jul 1, 2026, 8:25 PM
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For MondayBenzinga · Jun 1, 2026, 12:57 PM
HC Wainwright & Co. Downgrades Crescent Biopharma to NeutralBenzinga · Jun 1, 2026, 11:33 AM
Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027Benzinga · May 21, 2026, 9:45 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock